Cereda S - Search Results

1

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ, Cantore M. Giovannetti E, et al. Among authors: cereda s. Pharmacogenomics. 2011 Dec;12(12):1641-52. doi: 10.2217/pgs.11.109. Epub 2011 Oct 25. Pharmacogenomics. 2011. PMID: 22026922

2

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.

Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, Giovannetti E. Avan A, et al. Among authors: cereda s. Int J Cancer. 2013 Aug 15;133(4):1016-22. doi: 10.1002/ijc.28078. Epub 2013 Mar 4. Int J Cancer. 2013. PMID: 23390054 Free article.

3

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.

Cereda S, Reni M. Cereda S, et al. J Chemother. 2008 Aug;20(4):509-12. doi: 10.1179/joc.2008.20.4.509. J Chemother. 2008. PMID: 18676234

4

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

Reni M, Pasetto LM, Passardi A, Milella M, Mambrini A, Cereda S, Aprile G, Tronconi MC, Berardi R, Cordio S, Sartori N, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: cereda s. Dig Liver Dis. 2011 Mar;43(3):225-30. doi: 10.1016/j.dld.2010.09.010. Epub 2010 Nov 2. Dig Liver Dis. 2011. PMID: 21044873

5

Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.

Cereda S, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Brioschi M, Nicoletti R, Villa E. Cereda S, et al. Chemotherapy. 2011;57(2):156-61. doi: 10.1159/000324865. Epub 2011 Mar 31. Chemotherapy. 2011. PMID: 21454973 Clinical Trial.

6

Role of taxanes in pancreatic cancer.

Belli C, Cereda S, Reni M. Belli C, et al. Among authors: cereda s. World J Gastroenterol. 2012 Sep 7;18(33):4457-65. doi: 10.3748/wjg.v18.i33.4457. World J Gastroenterol. 2012. PMID: 22969215 Free PMC article.

7

New therapies for pancreatic cancer: current standard.

Reni M, Cereda S. Reni M, et al. Among authors: cereda s. JOP. 2007 Jan 9;8(1 Suppl):98-101. JOP. 2007. PMID: 17228141 No abstract available.

8

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.

Reni M, Cereda S, Galli L. Reni M, et al. Among authors: cereda s. Cancer Lett. 2007 Oct 18;256(1):25-8. doi: 10.1016/j.canlet.2007.04.009. Epub 2007 Jun 11. Cancer Lett. 2007. PMID: 17561341 Review.

9

A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.

Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, Cascinu S, Cantore M, Mazza E, Grisanti S. Reni M, et al. Among authors: cereda s. Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8. doi: 10.1007/s00280-007-0653-y. Epub 2008 Jan 3. Cancer Chemother Pharmacol. 2008. PMID: 18172650

10

XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.

Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E. Cereda S, et al. Anticancer Res. 2010 Nov;30(11):4785-90. Anticancer Res. 2010. PMID: 21115942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page